April 7, 2022
Washington, D.C. (April 7, 2022) – In response to the Centers for Medicare and Medicaid Services’ announcement on Aduhelm coverage, ACHP President and CEO Ceci Connolly issued the following statement:
“We commend the Administration’s decision today to limit Aduhelm coverage to Medicare beneficiaries participating in clinical trials. The Centers for Medicare and Medicaid Services has shown that its coverage decisions are guided by science and quality care for beneficiaries, and we applaud CMS for letting evidence and effectiveness prevail.
“Yet the work is not done. This unproven, expensive drug contributed to a price hike in Part B premiums—not to mention an increase in total health spending in the health care system. We urge CMS to reconsider premiums to remove this significant burden on the 60 million seniors in Medicare. Our seniors deserve no less.”
For more on ACHP’s position on the controversial Alzheimer’s drug, read ACHP’s blog on “How Aduhelm’s Price Cut Misses the Mark” and our recommendations to CMS on Aduhelm coverage.
The Alliance of Community Health Plans (ACHP) represents the nation’s top-performing non-profit health plans to improve affordability and outcomes in the health care system. ACHP member companies are provider-aligned health organizations that provide high-quality coverage and care to tens of millions of Americans. They are leading the industry in practical, proven reforms around primary care delivery, value-based payment and data-driven systems improvement.
ACHP advocates on behalf of its members and a unique approach to health care today, one that puts the patient at the center with health plans and clinical teams collaborating to improve health outcomes and reduce costs. Our advocacy focuses on providing policymakers with tested solutions being realized in communities nationwide and rooted in a model that is proven to deliver better value for patients, employers and taxpayers. Learn more at the ACHP website and follow us on Twitter for the latest health insights.
All media inquiries should be directed to: